Scientists from Cedars-Sinai Heart Institute reported on a study at the American College of Cardiology (ACC) conference in Chicago about stem cell therapy to treat severe heart failure. In the 109-person randomized, placebo-controlled study, they achieved a 37% reduction in deaths, cardiovascular hospitalizations and clinic visits over 12 months. This was the study's primary endpoint. The Phase IIb study did not meet its statistical significance for secondary endpoints including each of the endpoints within the composite primary endpoint, along with the total number of clinical events and assessments of patients' heart function and quality of life. Also in time to death, left ventricular assist device placement, heart transplantation or time to cardiovascular hospitalization was shorter for placebo-treated patients the data did not reach statistical significance. The treatment was ixmyelocel-T from micro-cap Vericel ($VCEL), which was down on the news. More